Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14999491 | 0.88 | HSPA5 (0.51) | HSPA5DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL6567449 | 0.81 | HSPA5 (0.41) | HSPA5DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL7786480 | 0.80 | NR1H4 (0.44) | HSPA5DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL6568742 | 0.78 | TNKS2 (0.42) | HSPA5DHFRPTGS2MAPTVCAM1 | |
| SCHEMBL15180049 | 0.77 | CA1 (0.50) | DHFRALDH1A1TSHRTDP1PTGS2 | |
| SCHEMBL14999492 | 0.77 | HSPA5 (0.46) | HSPA5DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL13368066 | 0.77 | RXRA (0.40) | DHFRALDH1A1TSHRTDP1PTGS2 | |
| SCHEMBL7792806 | 0.77 | GAA (0.41) | HSPA5TNFRSF1AVCAM1 | |
| SCHEMBL17072151 | 0.77 | ALDH1A1 (0.36) | HSPA5DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL13900816 | 0.76 | PTGS2 (0.54) | HSPA5DHFRALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505878-B2 | Catalysts and methods for polymer synthesis | NOVOMER, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150252145-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252145-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | HSPA5 3232/4885DHFR 941/4885ALDH1A1 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.